The Global Atopic Dermatitis Drugs Market will Hit $22 Billion by 2028, at a CAGR of 9.2%

Published Date: 30-Nov-2022

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Atopic Dermatitis Drugs Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Atopic Dermatitis Drugs Market size is expected to reach $22 billion by 2028, rising at a market growth of 9.2% CAGR during the forecast period.

The Oral segment is showcasing a CAGR of 9.4% during (2022 - 2028). Only in severe situations, when the disease has spread to vast portions of the body, or in the event of any complications with previous treatments, are oral corticosteroids administered. Azathioprine, methotrexate, cyclosporine, and mycophenolate mofetil are some of the common oral drugs.

The Biologics segment is leading the Global Atopic Dermatitis Drugs Market by Class in 2021 thereby, achieving a market value of $8.5 billion by 2028. Since biologics target the inflammatory mechanisms causing the disease rather than just treating the symptoms, they have a significant therapeutic benefit over traditional topical therapies. These medications have a competitive advantage due to their great specificity. In severe circumstances, such as second or third-line treatment for patients who have not responded to previous systemic medications, biologics are typically administered.

The North America market dominated the Global Atopic Dermatitis Drugs Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $9.5 billion by 2028.The Europe market is exhibiting a CAGR of 9% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 10.1% during (2022 - 2028).

Full Report: https://www.kbvresearch.com/atopic-dermatitis-drugs-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Pfizer Inc., Sanofi SA, AbbVie Inc., Galderma S.A., Eli Lilly and Company, Leo Pharma A/S, Regeneron Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and Incyte Corporation.

Global Atopic Dermatitis Drugs Market Segmentation

By Route of Administration

  • Injectable
  • Oral
  • Topical

By Class

  • Biologics
  • Calcineurin Inhibitors
  • Corticosteroids
  • PDE4 Inhibitors
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Pfizer Inc.
  • Sanofi SA
  • AbbVie Inc.
  • Galderma S.A.
  • Eli Lilly and Company
  • Leo Pharma A/S
  • Regeneron Pharmaceuticals Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Novartis AG
  • Incyte Corporation

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

North America Atopic Dermatitis Drugs Market size & Opportunities 2022-2028

Europe Atopic Dermatitis Drugs Market & Growth Forecast 2022-2028

Asia Pacific Atopic Dermatitis Drugs Market Share & Industry Outlook to 2028

LAMEA Atopic Dermatitis Drugs Market Growth, Trends & Forecasts 2022-2028

Request a Free Sample Copy


Why Choose Us

  • 24/7 Research support
    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Information security
    Your personal and confidential information is safe and secure.